Krystal Biotech (KRYS) Research & Development (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Research & Development of $14.5 million for Q2 2026, up 0.75% year-over-year from $14.4 million in Q2 2025, and down 5.3% on a QoQ basis from $15.3 million in Q1 2026.
Krystal Biotech (KRYS) Research & Development (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Research & Development for 11 years, with the latest figure at $14.5 million in Q2 2026.
- Research & Development for Q2 2026 came in at $14.5 million, up 0.75% year-over-year; the trailing twelve-month figure through Jun 2026 was $59.2 million (up 6.32% YoY), and the FY2025 annual result was $58.0 million, up 8.33% from the prior year.
- Research & Development declined to $14.5 million in Q2 2026, from $15.3 million in the prior quarter.
- Over five years, Research & Development peaked at $15.6 million in Q2 2024 and troughed at $9.3 million in Q1 2022.
- A 5-year average of $12.8 million and a median of $12.9 million in 2023 frame the typical range for Research & Development.
- The widest annual swing landed in 2022, when Research & Development jumped 89.41%; it then slipped 10.83% in 2024.
- A 5-year view of Research & Development shows it stood at $10.7 million in 2022, then increased by 5.87% to $11.4 million in 2023, then grew by 18.96% to $13.5 million in 2024, then grew by 9.36% to $14.8 million in 2025, then dropped by 1.87% to $14.5 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $14.5 million in Q2 2026, $15.3 million in Q1 2026, and $14.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 14.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.52 Mn |
| Mar 31, 2026 | 15.33 Mn |
| Dec 31, 2025 | 14.79 Mn |
| Sep 30, 2025 | 14.59 Mn |
| Jun 30, 2025 | 14.41 Mn |
| Mar 31, 2025 | 14.26 Mn |
| Dec 31, 2024 | 13.53 Mn |
| Sep 30, 2024 | 13.51 Mn |
| Jun 30, 2024 | 15.58 Mn |
| Mar 31, 2024 | 10.96 Mn |
| Dec 31, 2023 | 11.37 Mn |
| Sep 30, 2023 | 10.63 Mn |
| Jun 30, 2023 | 12.14 Mn |
| Mar 31, 2023 | 12.29 Mn |
| Dec 31, 2022 | 10.74 Mn |
| Sep 30, 2022 | 11.52 Mn |
| Jun 30, 2022 | 10.89 Mn |
| Mar 31, 2022 | 9.31 Mn |
| Dec 31, 2021 | 9.01 Mn |
| Sep 30, 2021 | 6.08 Mn |